Combining Nanoparticles and Checkpoint Blockade Therapy
- Detailed Technology Description
- In situ immunization leadsto tumor cell death by providing antigen-presenting cells, such as dendriticcells (DCs), with tumor antigens that result in a therapeutic anticancer immuneresponse. The market size for in situ immunization is expected to reach $34 billionby 2024, which is a large increase from $34 billion expected in 2019.
- *Abstract
-
ProfessorsSalem and Weiner have developed novel formulations and methods for treatingpatients with solid malignant tumors. Combinations of cytotoxic particles,immune checkpoint inhibitors, and/or T-cell stimulatory agent are injecteddirectly into the tumor. PLGAmicroparticles loaded with chemotherapy and immunotherapy drugs induceimmunogenic tumor cell death and enhance tumor antigen presentation. In vivotests show that these drugs can kill both B and T lymphoma cells and are lesstoxic to dendritic cells than current methods. Combining the drugs used for thistreatment with checkpoint blockade therapy cured suppressed injected anddistant tumors, leading to tumor free mice.
Advantages
- Efficientand safe tool for in situimmunization
- Testedto cure murine B lymphoma model in mice
- Safeco-delivery with use of PLGA microparticles
- Effectiveagainst B and T lymphoma cells
- Lowtoxicity to dendritic cells
- *Licensing
- Email: uirf-marketing@uiowa.eduPhone: (319) 335-4546
- Country/Region
- USA
For more information, please click Here
